Skip to main content
. 2014 Feb 10;32(8):783–790. doi: 10.1200/JCO.2013.49.3726

Fig 4.

Fig 4.

Kaplan-Meier estimates of (A) progression-free survival (PFS) and (B) overall survival (OS) by treatment (procarbazine, lomustine, and vincristine [PCV] plus radiotherapy [RT] or RT) for G allele carriers. Hazard ratio (HR) for (A) PFS was 0.42 (95% CI, 0.24 to 0.71; P = .001); HR for (B) OS was 0.65 (95% CI, 0.36 to 1.16; P = .14).